Compare iShares MSCI Hong Kong ETF (EWH) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs TransMedics Group Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.05 (market cap $1.16B), while TransMedics Group Inc trades at $77.47 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 2.4× iShares MSCI Hong Kong ETF's market cap, and iShares MSCI Hong Kong ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and TransMedics Group Inc for 24 Days on average.
| EWH | TMDX | |
|---|---|---|
Market Cap | $1.16B | $2.74B |
Volume | 3,176,523 | 949,331 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $150.42 |
52-Week Low | $20.66 | $61.99 |
Typical Hold Time | 61 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.04, up 2.13% in the last 24 hours. The technical outlook is bearish, with moving averages signaling a downtrend and key support at $21. Recent news highlights volatility in the Hang Seng Index, driven by Federal Reserve decisions and geopolitical tensions. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
The ETF faces headwinds from Hong Kong market weakness and institutional selling, but oversold conditions per RSI may offer tactical opportunities. Risks include ongoing U.S.-China tensions and economic pressures. Investors should weigh exposure to Hong Kong equities against broader market risks.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
